Dicot Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Dicot Pharma CEO'su Elin Trampe, Apr2022 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı SEK 1.79M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.037% ine doğrudan sahiptir ve bu hisseler SEK 144.09K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 2.6 yıldır.

Anahtar bilgiler

Elin Trampe

İcra Kurulu Başkanı

SEK 1.8m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	2.6yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	2.6yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Nov 12

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23

CEO Tazminat Analizi

Elin Trampe'un ücretlendirmesi Dicot Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 53m
Jun 30 2024	n/a	n/a	-SEK 51m
Mar 31 2024	n/a	n/a	-SEK 48m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 44m
Sep 30 2023	n/a	n/a	-SEK 37m
Jun 30 2023	n/a	n/a	-SEK 34m
Mar 31 2023	n/a	n/a	-SEK 32m
Dec 31 2022	SEK 1m	SEK 1m	-SEK 32m

Tazminat ve Piyasa: Elin 'nin toplam tazminatı ($USD 163.74K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 236.52K ).

Tazminat ve Kazançlar: Elin şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Elin Trampe (44 yo)

2.6yrs

Görev süresi

SEK 1,794,430

Tazminat

Ms. Elin Trampe serves as Chief Executive Officer at Dicot Pharma AB (formerly known as Dicot AB (publ))since April 1, 2022. She served as Vice President for Dicot Pharma AB (formerly known as Dicot AB (pu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Elin Trampe	Chief Executive Officer	2.6yrs	SEK 1.79m	0.037% SEK 144.1k
Jarl Wikberg	Founder & Chief Scientific Officer	no data	SEK 67.75k	Veri yok
Bjorn Petersson	Chief Financial Officer	2.7yrs	Veri yok	Veri yok
Mats Silvander	Chief Technical Officer	1.3yrs	Veri yok	Veri yok
Charlotta Gauffin	Chief Scientific Officer	2.3yrs	Veri yok	0.017% SEK 66.7k
Julie Silber	Director of Investor Relations	4.9yrs	Veri yok	Veri yok
Gabriela Urquilla	Director of Communications	4.9yrs	Veri yok	Veri yok
Hakan Wickholm	Chief Business Officer	no data	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: DICOT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan-Eric Österlund	Independent Director	1.5yrs	Veri yok	Veri yok
Fredrik Buch	Independent Director	2.6yrs	SEK 75.00k	Veri yok
Michael Zell	Independent Director	2.6yrs	SEK 75.00k	0.46% SEK 1.8m
Per-Goran Gillberg	Independent Director	3.5yrs	SEK 116.90k	0.034% SEK 132.0k
Eva Saers	Independent Chairman of the Board	4yrs	SEK 170.00k	0.046% SEK 181.1k
Mikael von Euler	Independent Director	no data	SEK 86.40k	Veri yok

2.6yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DICOT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Dicot Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Dicot Pharma AB Appoints Håkan Wickholm as Chief Business Officer

Independent Chairman of the Board recently bought kr58k worth of stock

Independent Chairman of the Board recently bought kr51k worth of stock

Director exercised options to buy kr169k worth of stock.

Dicot AB, Annual General Meeting, May 06, 2024

Director exercised options to buy kr194k worth of stock.

Recent updates

Dicot Pharma AB Appoints Håkan Wickholm as Chief Business Officer

Independent Chairman of the Board recently bought kr58k worth of stock

Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation

Dicot Pharma Announces Initiation of Phase 2A Clinical Study

New major risk - Shareholder dilution

Independent Chairman of the Board recently bought kr51k worth of stock

Dicot Pharma AB (publ) Provides an Operational Update

Dicot Pharma AB to Report Q2, 2024 Results on Aug 23, 2024

Dicot Pharma Announces Clinical Trial Application for Phase 2A Trial

Dicot Pharma AB to Report Q3, 2024 Results on Aug 01, 2024

Dicot Pharma AB Completes a Pre-IND Meeting with FDA

Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs

Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024

Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial

New major risk - Financial position

Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024

Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study

Dicot Applies for Patent Covering New Manufacturing Technology

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year

Director exercised options to buy kr169k worth of stock.

New minor risk - Share price stability

Dicot AB, Annual General Meeting, May 06, 2024

Dicot AB Initiates Repeated Dosing in Phase I Study

The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023

Dicot AB to Report Q3, 2023 Results on Oct 31, 2023

Dicot AB Applies for International Patent Protection

Dicot AB Announces First Participants Dosed in Phase 1 Trial

Dicot AB Applies for US Patent

Dicot AB (publ) Announces Clinical Phase 1 Study Starts

Dicot AB Receives Approval to Start Phase 1 Clinical Trial

Dicot AB to Report Q2, 2023 Results on Aug 24, 2023

Director exercised options to buy kr194k worth of stock.

New major risk - Share price stability

Dicot AB (publ) Submits Application to Start Clinical Phase 1 Trial

Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01

Dicot's Study Drug Arrives in Sweden

Dicot AB Appoints Mats Silvander as New chief technical officer

Dicot AB Study Results Presented at European Society for Sexual Medicine

Dicot AB to Report Fiscal Year 2022 Results on Feb 27, 2023

No independent directors

Dicot AB Announces That It's Latest Study of the Mechanism of Action of LIB-01 Assumed to Be the Next Generation of Potency Drugs

Dicot AB Announces Successful First Regulatory Meeting for LIB-01

Dicot AB to Report Q3, 2022 Results on Nov 15, 2022

Dicot AB Reports Good Results from Preclinical Toxicology Studies

Dicot AB to Report Q2, 2022 Results on Aug 25, 2022

Dicot AB Moves Forward with New Patent Application

First quarter 2022 earnings released

No independent directors

Dicot AB Appoints Charlotta Gauffin as Chief Scientific Officer

Dicot AB Announces Board Changes

Dicot to Develop LIB-01 to an Oral Drug

Dicot AB Announces CEO Changes

Dicot Announces CFO Changes, Effective March 7, 2022

Dicot Announces That the Results of Dicot's Drug Candidate Will Be Presented At the European Society for Sexual Medicine

Dicot AB Announces Election of Eva Sjökvist Saers as the Chairman of Board, At the Extraordinary General Meeting Held on February 9, 2021

Dicot AB (publ) Broadens Testing of the Drug Candidate LIB-01

New 90-day low: kr0.94

Dicot Initiates Toxicology Studies Before Applying for Clinical Trials

New 90-day low: kr0.99

New 90-day low: kr1.06

Dicot Ordinary Shares to Be Deleted from Other OTC

New 90-day low: kr1.11

New 90-day low: kr1.33

Dicot AB Continues Studies with Pelvipharm to Generate Knowledge About Treatment Times, Doses and Libiguin's® Mechanism of Action

Dicot AB Announces That Sustainable Supply of Raw Material Important to Dicot

Dicot AB to Report Q2, 2020 Results on Aug 27, 2020